SS1
MCID: SRC025
MIFTS: 70

Sarcoidosis 1 (SS1)

Categories: Bone diseases, Endocrine diseases, Eye diseases, Genetic diseases, Immune diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Sarcoidosis 1

MalaCards integrated aliases for Sarcoidosis 1:

Name: Sarcoidosis 1 56 73 6
Sarcoidosis 56 12 74 52 58 73 54 42 43 15 62 71 32
Boeck Sarcoid 56 12 58 73
Sarcoidosis, Susceptibility to, 1 56 13
Besnier-Boeck-Schaumann Disease 58 73
Ss1 56 73
Sarcoidosis, Susceptibility to, Type 1 39
Lymphogranulomatosis 12
Schaumann's Disease 52
Sarcoid of Boeck 52
Hodgkin Disease 71

Characteristics:

Orphanet epidemiological data:

58
sarcoidosis
Inheritance: Multigenic/multifactorial; Prevalence: 1-5/10000 (Worldwide),1-5/10000 (Europe); Age of onset: Adult;

OMIM:

56
Miscellaneous:
generalized fatigue
onset usually before age 40 years
systemic granulomatous disease
u.s. frequency higher in blacks than whites

Inheritance:
autosomal dominant


HPO:

31
sarcoidosis 1:
Inheritance autosomal dominant inheritance sporadic


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases
Rare renal diseases
Rare respiratory diseases
Rare systemic and rhumatological diseases
Rare endocrine diseases


Summaries for Sarcoidosis 1

NIH Rare Diseases : 52 Sarcoidosis is an inflammatory disease characterized by the development and growth of tiny lumps of cells called granulomas. If these tiny granulomas grow and clump together in an organ , they can affect the organ's structure and function. Overtime, this can lead to permanent scarring or thickening of the organ tissue (also called fibrosis). Although the granulomas can be found in almost any part of the body, they occur most commonly in the lungs and lymph nodes . Signs and symptoms of sarcoidosis vary based on the location of the granulomas and the severity of the condition. The exact cause of sarcoidosis is poorly understood. In many cases, treatment is not necessary and sarcoidosis will resolve on its own. However, therapies such as corticosteroids , immunosuppressants, and antimalarial drugs, are available to control symptoms, prevent complications, and improve outcomes.

MalaCards based summary : Sarcoidosis 1, also known as sarcoidosis, is related to cardiac sarcoidosis and blau syndrome, and has symptoms including snoring and coughing. An important gene associated with Sarcoidosis 1 is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Riociguat have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and lymph node, and related phenotypes are fatigue and fever

Disease Ontology : 12 A hypersensitivity reaction type IV disease characterized by the growth of collections of inflammatory cells (granulomas) in multiple organs.

MedlinePlus : 42 Sarcoidosis is a disease that leads to inflammation, usually in your lungs, skin, or lymph nodes. It starts as tiny, grain-like lumps, called granulomas. Sarcoidosis can affect any organ in your body. No one is sure what causes sarcoidosis. It affects men and women of all ages and races. It occurs mostly in people ages 20 to 50, African Americans, especially women, and people of Northern European origin. Many people have no symptoms. If you have symptoms, they may include Cough Shortness of breath Weight loss Night sweats Fatigue Tests to diagnose sarcoidosis include chest x-rays, lung function tests, and a biopsy. Not everyone who has the disease needs treatment. If you do, prednisone, a type of steroid, is the main treatment. NIH: National Heart, Lung, and Blood Institute

UniProtKB/Swiss-Prot : 73 Sarcoidosis 1: An idiopathic, systemic, inflammatory disease characterized by the formation of immune granulomas in involved organs. Granulomas predominantly invade the lungs and the lymphatic system, but also skin, liver, spleen, eyes and other organs may be involved.

PubMed Health : 62 About sarcoidosis: Sarcoidosis (sar-koy-DO-sis) is a disease of unknown cause that leads to inflammation. This disease affects your body’s organs. Normally, your immune system defends your body against foreign or harmful substances. For example, it sends special cells to protect organs that are in danger. These cells release chemicals that recruit other cells to isolate and destroy the harmful substance. Inflammation occurs during this process. Once the harmful substance is gone, the cells and the inflammation go away. In people who have sarcoidosis, the inflammation doesn't go away. Instead, some of the immune system cells cluster to form lumps called granulomas (gran-yu-LO-mas) in various organs in your body.

Wikipedia : 74 Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as... more...

More information from OMIM: 181000

Related Diseases for Sarcoidosis 1

Diseases in the Sarcoidosis 1 family:

Sarcoidosis 2 Sarcoidosis 3

Diseases related to Sarcoidosis 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1599)
# Related Disease Score Top Affiliating Genes
1 cardiac sarcoidosis 35.1 TNF IL1B IFNG ACE
2 blau syndrome 34.7 TNF NOD2 IL1B
3 skin sarcoidosis 34.5 TNF ACE
4 uveoparotid fever 33.6 TNF ACE
5 beryllium disease 33.5 TNF HLA-DRB1
6 orofacial granulomatosis 33.5 TNF NOD2 IFNG CXCR3 CCL3 BTNL2
7 retinal vasculitis 33.4 TNF CCR6 CCL2 ACE
8 intermediate uveitis 33.3 TNF IL2RA IFNG HLA-DRB1 CXCR3 CCR6
9 interstitial lung disease 33.2 TNF IL1B IL18 IFNG CXCL9 CHIT1
10 melkersson-rosenthal syndrome 32.8 TNF ACE
11 uveitis 32.2 TNF NOD2 IL2RA IL1B IFNG CXCR3
12 pulmonary fibrosis 32.1 IL1B CXCR3 CCL3 CCL2 CCL18
13 lung disease 31.9 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
14 glomerulonephritis 31.7 SCGB1A1 IL1B CCL2 ACE
15 exanthem 31.7 TNF IL1B IFNG CCR6 ACE
16 extrinsic allergic alveolitis 31.7 IL2RA IL1B IL18 CXCR3 CCR6 CCL3
17 allergic hypersensitivity disease 31.7 TNF IFNG CCR6 CCL3
18 panuveitis 31.6 TNF SERPINA3 HLA-DRB1 CCR6 ACE
19 leprosy 3 31.6 TNF NOD2 IL1B IFNG HLA-DRB1 CCR6
20 autoimmune disease 31.6 TNF IL2RA IL1B IL18 IFNG HLA-DRB1
21 pulmonary tuberculosis 31.6 TNF IL2RA IL1B IL18 IL12RB1 IFNG
22 posterior uveitis 31.6 TNF IL2RA IFNG CCR6
23 lymphopenia 31.6 IL2RA IL18 IFNG CCR6
24 crohn's disease 31.6 TNF NOD2 IL1B IL18 IFNG HLA-DRB1
25 respiratory failure 31.6 TNF SERPINA3 SCGB1A1 IL1B CCR6 ACE
26 myocarditis 31.6 TNF IL1B IL18 IL12RB1 IFNG CCL3
27 chronic beryllium disease 31.5 TNF IFNG HLA-DRB1
28 spondylitis 31.5 TNF NOD2 IFNG CCR6
29 histoplasmosis 31.5 TNF IL12RB1 IFNG HLA-DRB1 CCR6
30 macular retinal edema 31.5 TNF IL1B CCL2 ACE
31 primary biliary cirrhosis 31.5 TNF IL1B IL12RB1 IFNG HLA-DRB1 CXCR3
32 mycobacterium tuberculosis 1 31.5 TNF SERPINA3 NOD2 IL18 IL12RB1 IFNG
33 myositis 31.5 TNF SERPINA3 IL1B IFNG HLA-DRB1 CCL2
34 anthracosis 31.5 TNF IL1B CCL2
35 optic nerve disease 31.4 TNF SERPINA3 IL1B CCR6 ACE
36 pulmonary fibrosis, idiopathic 31.4 TNF SCGB1A1 IL1B IL18 IFNG CXCR3
37 choroiditis 31.4 TNF IFNG ACE
38 iritis 31.4 TNF NOD2 CCR6 ACE
39 purpura 31.4 TNF IFNG ACE
40 histiocytosis 31.4 TNF SERPINA3 IFNG CCR6
41 pneumoconiosis 31.4 TNF SCGB1A1 IL1B HLA-DRB1 CCL2
42 pleurisy 31.4 TNF IFNG CCL3 CCL2
43 hydrocephalus 31.4 TNF SERPINA3 IL18 IFNG ACE
44 cryptococcosis 31.4 TNF IFNG CCR6
45 systemic scleroderma 31.4 TNF IL1B IFNG CCR6 ACE
46 syphilis 31.4 TNF SERPINA3 IFNG HLA-DRB1 CCR6 ACE
47 pericarditis 31.4 TNF IL1B IFNG ACE
48 berylliosis 31.3 IFNG HLA-DRB1 ACE
49 ulcerative colitis 31.3 TNF NOD2 IL1B IFNG HLA-DRB1 CCR6
50 common variable immunodeficiency 31.3 TNF NOD2 IL2RA IL1B IL12RB1 IFNG

Graphical network of the top 20 diseases related to Sarcoidosis 1:



Diseases related to Sarcoidosis 1

Symptoms & Phenotypes for Sarcoidosis 1

Human phenotypes related to Sarcoidosis 1:

58 31 (show top 50) (show all 93)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 31 frequent (33%) Frequent (79-30%) HP:0012378
2 fever 58 31 frequent (33%) Frequent (79-30%) HP:0001945
3 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
4 weight loss 58 31 frequent (33%) Frequent (79-30%) HP:0001824
5 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
6 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
7 thrombocytopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001873
8 joint swelling 58 31 frequent (33%) Frequent (79-30%) HP:0001386
9 uveitis 58 31 frequent (33%) Frequent (79-30%) HP:0000554
10 leukopenia 58 31 frequent (33%) Frequent (79-30%) HP:0001882
11 erythema nodosum 58 31 frequent (33%) Frequent (79-30%) HP:0012219
12 increased t cell count 31 frequent (33%) HP:0100828
13 cataract 58 31 occasional (7.5%) Occasional (29-5%) HP:0000518
14 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
15 blindness 58 31 occasional (7.5%) Occasional (29-5%) HP:0000618
16 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
17 portal hypertension 58 31 occasional (7.5%) Occasional (29-5%) HP:0001409
18 emphysema 58 31 occasional (7.5%) Occasional (29-5%) HP:0002097
19 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
20 subcutaneous nodule 58 31 occasional (7.5%) Occasional (29-5%) HP:0001482
21 pulmonary fibrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002206
22 heart block 58 31 occasional (7.5%) Occasional (29-5%) HP:0012722
23 alopecia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001596
24 diabetes insipidus 58 31 occasional (7.5%) Occasional (29-5%) HP:0000873
25 glaucoma 58 31 occasional (7.5%) Occasional (29-5%) HP:0000501
26 facial palsy 58 31 occasional (7.5%) Occasional (29-5%) HP:0010628
27 nephrocalcinosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000121
28 nephrolithiasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000787
29 hypercalciuria 58 31 occasional (7.5%) Occasional (29-5%) HP:0002150
30 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
31 hepatic failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001399
32 abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0011024
33 bone cyst 58 31 occasional (7.5%) Occasional (29-5%) HP:0012062
34 keratoconjunctivitis sicca 58 31 occasional (7.5%) Occasional (29-5%) HP:0001097
35 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
36 upper airway obstruction 58 31 occasional (7.5%) Occasional (29-5%) HP:0002781
37 pneumothorax 58 31 occasional (7.5%) Occasional (29-5%) HP:0002107
38 proximal muscle weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003701
39 bronchiectasis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002110
40 tubulointerstitial nephritis 58 31 occasional (7.5%) Occasional (29-5%) HP:0001970
41 dacryocystitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000620
42 hypopigmentation of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0001010
43 scarring 58 31 occasional (7.5%) Occasional (29-5%) HP:0100699
44 skin plaque 58 31 occasional (7.5%) Occasional (29-5%) HP:0200035
45 chylothorax 58 31 occasional (7.5%) Occasional (29-5%) HP:0010310
46 ventricular tachycardia 58 31 occasional (7.5%) Occasional (29-5%) HP:0004756
47 hyperpigmentation of the skin 58 31 occasional (7.5%) Occasional (29-5%) HP:0000953
48 maculopapular exanthema 58 31 occasional (7.5%) Occasional (29-5%) HP:0040186
49 abnormal reproductive system morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0012243
50 abnormal liver parenchyma morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0030146

Symptoms via clinical synopsis from OMIM:

56
Head And Neck Eyes:
photophobia
glaucoma
uveitis
blurred vision
iridocyclitis
more
Respiratory:
dyspnea
cough

Abdomen Gastrointestinal:
anorexia
associated inflammatory bowel disease

Immunology:
generalized lymphadenopathy
hyperglobulinemia
activated t-helper cells
activated mononuclear phagocytes
exaggerated cellular immune processes

Head And Neck Mouth:
enlarged salivary glands

Abdomen Liver:
hepatomegaly may occur
elevated liver function tests may occur

Neurologic Central Nervous System:
neurosarcoidosis (5-16% of patients)

Metabolic Features:
fever

Growth Weight:
weight loss

Laboratory Abnormalities:
hypercalciuria
elevated erythrocyte sedimentation rate (esr)
elevated serum angiotensin-converting enzyme (ace)
positive kveim-siltzbach skin test
mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip)

Skeletal:
polyarthritis
bone cysts

Respiratory Lung:
bilateral hilar adenopathy
pulmonary parenchymal infiltration
pulmonary function tests show interstitial lung disease

Abdomen Spleen:
splenomegaly may occur

Hematology:
bone marrow involvement may cause pancytopenia

Clinical features from OMIM:

181000

UMLS symptoms related to Sarcoidosis 1:


snoring, coughing

MGI Mouse Phenotypes related to Sarcoidosis 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.7 ACE CCR6 CXCR3 IFNG IL12RB1 IL18
2 immune system MP:0005387 9.44 ACE CCL2 CCR6 CHIT1 CXCR3 IFNG

Drugs & Therapeutics for Sarcoidosis 1

PubMed Health treatment related to Sarcoidosis 1: 62

Not everyone who has sarcoidosis needs treatment . Sometimes the disease goes away on its own. Whether you need treatment and what type of treatment you need depend on your signs and symptoms, which organs are affected, and whether those organs are working well. If the disease affects certain organs —such as your eyes , heart , or brain —you'll need treatment even if you don't have any symptoms. In either case, whether you have symptoms or not, you should see your doctor for ongoing care. He or she will want to check to make sure that the disease isn't damaging your organs . For example, you may need routine lung function tests to make sure that your lungs are working well. If the disease isn't worsening, your doctor may watch you closely to see whether the disease goes away on its own. If the disease does start to get worse, your doctor can prescribe treatment . The goals of treatment include: Relieving symptoms Improving organ function Controlling inflammation and reducing the size of granulomas (inflamed lumps) Preventing pulmonary fibrosis (lung scarring ) if your lungs are affected Your doctor may prescribe topical treatments and/or medicines to treat the disease.

Drugs for Sarcoidosis 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 457)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Riociguat Approved Phase 4 625115-55-1
3
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
4
Remifentanil Approved Phase 4 132875-61-7 60815
5
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Racepinephrine Approved Phase 4 329-65-7 838
8
Iloprost Approved, Investigational Phase 4 78919-13-8 6443959
9
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
10
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Etoposide Approved Phase 4 33419-42-0 36462
13
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
14
Epirubicin Approved Phase 4 56420-45-2 41867
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
Nicotine Approved Phase 4 54-11-5 942 89594
17
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
18
leucovorin Approved Phase 4 58-05-9 6006 143
19
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
20
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
21
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
22
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
23 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
26
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
27
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
28
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
29
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
30 Adrenergic alpha-Agonists Phase 4
31 Narcotics Phase 4
32 Adrenergic Agents Phase 4
33 Epinephryl borate Phase 4
34 Analgesics, Opioid Phase 4
35 Adrenergic Agonists Phase 4
36 Dopamine Agents Phase 4
37 Dexmethylphenidate Hydrochloride Phase 4
38 Anesthetics, General Phase 4
39 Hypnotics and Sedatives Phase 4
40 Anesthetics, Intravenous Phase 4
41 Gastrointestinal Agents Phase 4
42 Protective Agents Phase 4
43 Neuroprotective Agents Phase 4
44 Antiemetics Phase 4
45 Etoposide phosphate Phase 4
46 Ergocalciferols Phase 4
47 Citrate Phase 4
48 Vitamin D2 Phase 4
49 Adrenocorticotropic Hormone Phase 4
50 Melanocyte-Stimulating Hormones Phase 4

Interventional clinical trials:

(show top 50) (show all 991)
# Name Status NCT ID Phase Drugs
1 Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS) Unknown status NCT01830959 Phase 4 Roflumilast;Placebo
2 ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS) Unknown status NCT02188017 Phase 4 Acthar gel
3 A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension Unknown status NCT02625558 Phase 4 Riociguat;Placebo
4 Pirfenidone for Progressive Fibrotic Sarcoidosis Unknown status NCT03260556 Phase 4 Pirfenidone;Placebos
5 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
6 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
7 Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00403650 Phase 4 Iloprost
8 Randomized, Double-Blind, Placebo-Controlled Study of Dexmethylphenidate Hydrochloride, (d-MPH) in the Treatment of Fatigue in Sarcoidosis Subjects. Completed NCT00361387 Phase 4 d-methylphenidate
9 Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel Completed NCT02298491 Phase 4 H.P. Acthar Gel
10 Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial. Completed NCT02246023 Phase 4
11 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab vedotin
12 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
13 ACTHAR Therapy for Central Nervous System Sarcoidosis Recruiting NCT02920710 Phase 4 Repository Corticotropin Injection
14 d68Ga-DOTATATE PET/CT Assessment of Cardiac Sarcoidosis Recruiting NCT03549598 Phase 4 68Ga-DOTATATE PET/CT;18FDG PET/CT scan;13NH3 PET/CT scan
15 Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial Recruiting NCT03265405 Phase 4 Low dose prednisolone;Medium dose prednisolone
16 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Recruiting NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
17 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
18 Vitamin D Homeostasis in Sarcoidosis Active, not recruiting NCT03621553 Phase 4 Ergocalciferol;Placebo;Calcium Citrate with Vitamin D2
19 A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of Acthar Gel in Subjects With Pulmonary Sarcoidosis Active, not recruiting NCT03320070 Phase 4 Acthar Gel;Placebo
20 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
21 The PREDMETH Trial: Effectiveness of Methotrexate Versus Prednisolone as First-line Therapy for Pulmonary Sarcoidosis - A Randomized Controlled Trial Not yet recruiting NCT04314193 Phase 4 Methotrexate;Prednisolone
22 Use of CXCL9 as a Biomarker of Acthar Efficacy Not yet recruiting NCT02523092 Phase 4 Acthar gel
23 Modulation of Pulmonary Sarcoidosis by Nicotinic Acetylcholine Receptors Suspended NCT00701207 Phase 4 nicotine patch
24 Assessment of the Safety, Side Effects and Efficacy of Interventional Cryotherapy for the Eradication of Benign Airway Disease("ICE THE BAD") Terminated NCT00747461 Phase 4
25 Corticosteroid Sparing Effect of Methotrexate in Patients With Sarcoid- Associated Uveitis: A Double Blind, Randomized, Placebo Controlled-study -UVEXATE Terminated NCT00918554 Phase 4 Methotrexate;Placebo
26 Use of Thalidomide in Chronic Uveitis Terminated NCT00314665 Phase 4 Thalidomide
27 Protocol for a Randomized, Placebo-Controlled, Double-Blinded Trial to Study the Effects of Supplementary Omega-3 Fatty Acids on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
28 CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial Withdrawn NCT01210677 Phase 4 Prednisone
29 ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study Unknown status NCT02155803 Phase 2, Phase 3 ACTHAR Gel (adrenocorticotropic hormone)
30 ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial Unknown status NCT02348905 Phase 2, Phase 3 ACTHAR Gel 40 units twice weekly;ACTHAR Gel 80 units twice weekly.
31 Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis Unknown status NCT02824419 Phase 2, Phase 3 Methionine;DOTANOC
32 Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis Unknown status NCT01920919 Phase 3 Dexamethasone;Placebo
33 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
34 Phase III Randomized Trial of Adjuvant Involved-Field Radiotherapy vs No Adjuvant Therapy Following Remission Induction With MOPP/ABV Hybrid Chemotherapy in Patients With Stage III/IV Hodgkin's Disease Unknown status NCT00002462 Phase 3 doxorubicin hydrochloride;mechlorethamine hydrochloride;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
35 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
36 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
37 BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma Unknown status NCT00049595 Phase 3 ABVD regimen;BEACOPP regimen;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;prednisone;procarbazine hydrochloride;vinblastine sulfate;vincristine sulfate
38 Optic Neuritis Treatment Trial (ONTT) Unknown status NCT00000146 Phase 3 Methylprednisolone;Prednisone
39 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
40 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children With Newly Diagnosed High Risk Hodgkin Lymphoma Unknown status NCT01026220 Phase 3 doxorubicin hydrochloride;liposomal vincristine sulfate;vinorelbine tartrate;cyclophosphamide;etoposide phosphate;prednisone;ifosfamide
41 Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00851929 Phase 2, Phase 3 Ambrisentan
42 Tadalafil for Sarcoidosis Associated Pulmonary Hypertension Completed NCT01324999 Phase 2, Phase 3 Tadalafil
43 Randomized Controlled Trial of Thalidomide vs Placebo in Skin Sarcoidosis Completed NCT00305552 Phase 3 THALIDOMIDE
44 The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis Completed NCT00794274 Phase 2, Phase 3 CC-100004
45 Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. Completed NCT02200146 Phase 3 Prednisone;Hydroxychloroquine + Prednisone
46 Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis. Completed NCT01687517 Phase 3 Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
47 Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV) Completed NCT00443677 Phase 3 COPPEBVCAD vs BEACOPP vs ABVD
48 Use of Armodafinil (R-modafinil) for Fatigue in Sarcoidosis Completed NCT00555347 Phase 2, Phase 3 Armodafinil;Placebo
49 Endosonography (EUS and EBUS) vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis: a Randomized Trial Completed NCT00872612 Phase 3
50 Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension Completed NCT00581607 Phase 2, Phase 3 Bosentan;Placebo;Bosentan;Placebo

Search NIH Clinical Center for Sarcoidosis 1

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cochrane evidence based reviews: sarcoidosis

Genetic Tests for Sarcoidosis 1

Anatomical Context for Sarcoidosis 1

MalaCards organs/tissues related to Sarcoidosis 1:

40
Lung, T Cells, Lymph Node, Testes, Skin, Heart, Bone

Publications for Sarcoidosis 1

Articles related to Sarcoidosis 1:

(show top 50) (show all 23807)
# Title Authors PMID Year
1
HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. 6 56 61
14508706 2003
2
Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. 56 61 54
15702130 2005
3
Sarcoidosis is associated with a truncating splice site mutation in BTNL2. 54 61 6
15735647 2005
4
Association between IFNA genotype and the risk of sarcoidosis. 56 54 61
15004750 2004
5
Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. 56 61
17591867 2007
6
Demographic-related variations in posterior segment ocular sarcoidosis. 56 61
15019390 2004
7
Results from a genome-wide search for predisposing genes in sarcoidosis. 56 61
11549543 2001
8
Design of a case control etiologic study of sarcoidosis (ACCESS). ACCESS Research Group. 61 56
10580780 1999
9
[Familial sarcoidosis. 4 cases from 2 families]. 56 61
3070740 1988
10
Genetic aspects of sarcoidosis. Class II histocompatibility antigens and a family study. 61 56
3827423 1987
11
Familial occurrence of sarcoidosis and Crohn's disease. 56 61
6134089 1983
12
Familial sarcoidosis with multiple occurrences in eleven families: a possible mechanism of inheritance. 61 56
1067023 1976
13
Familial sarcoidosis: a possible genetic influence. 56 61
1067024 1976
14
Sarcoidosis and Crohn disease in siblings. 56 61
5558992 1971
15
Familial sarcoidosis. Report of four siblings with acute sarcoidosis. 56 61
5558993 1971
16
SARCOIDOSIS. I. FAMILIAL OCCURRENCE. II. PSEUDOTUMOR CEREBRI AND UNUSUAL SKIN LESIONS. 56 61
14104643 1964
17
Epidemiologic investigations of sarcoidosis. III. Serum proteins; syphilis; association with tuberculosis: familial aggregation. 56 61
13874291 1961
18
Immune response biomarkers as indicators of sarcoidosis presence, prognosis, and possible treatment: An Immunopathogenic perspective. 61 42
31917262 2020
19
Sarcoidosis and the alpha chemokine MIG. 42 61
32141489 2020
20
Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns. 61 42
31942239 2019
21
Sarcoidosis following Cushing's syndrome: A report of two cases and review of the literature. 61 54
20162506 2010
22
The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. 61 54
20070603 2010
23
NOD2-associated diseases: Bridging innate immunity and autoinflammation. 61 54
19467619 2010
24
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. 61 54
19147181 2010
25
Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. 61 54
19910611 2010
26
CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. 61 54
19679608 2010
27
Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case. 54 61
20022779 2010
28
Elevation of surfactant protein D, a pulmonary disease biomarker, in the sera of uveitis patients with sarcoidosis. 61 54
20151281 2010
29
Lack of association of immune-response-gene polymorphisms with susceptibility to sarcoidosis in Slovenian patients. 54 61
20082271 2010
30
A case of early-onset sarcoidosis with a six-base deletion in the NOD2 gene. 61 54
19854854 2010
31
Plasma chitotriosidase and CCL18 as surrogate markers for granulomatous macrophages in sarcoidosis. 54 61
19808030 2010
32
Targeting the TNF-alpha pathway in sarcoidosis. 61 54
20001207 2010
33
Angiotensin I-converting enzyme mutation (Trp1197Stop) causes a dramatic increase in blood ACE. 54 61
20011602 2009
34
Sarcoidosis during anti-tumor necrosis factor-alpha therapy: no relapse after rechallenge. 61 54
19966199 2009
35
Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. 61 54
19755199 2009
36
[Radiographic healing of sarcoid bone erosion]. 61 54
19756665 2009
37
Antimycobacterial immune responses in patients with pulmonary sarcoidosis. 61 54
20298409 2009
38
CXCR3 ligands are augmented during the pathogenesis of pulmonary sarcoidosis. 54 61
19386686 2009
39
Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. 54 61
19225544 2009
40
Chemokine receptors in a regulation of interstitial lung fibrosis and inflammation. 61 54
19842835 2009
41
Hypothesis: sarcoidosis is a STAT1-mediated disease. 54 61
19464956 2009
42
18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. 54 61
19259660 2009
43
Cardiac infiltration in early-onset sarcoidosis associated with a novel heterozygous mutation, G481D, in CARD15. 54 61
19359344 2009
44
Cytokine gene polymorphisms and BALF cytokine levels in interstitial lung diseases. 61 54
19117745 2009
45
International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). 61 54
19585358 2009
46
Protein levels of CC chemokine ligand (CCL)15, CCL16 and macrophage stimulating protein in patients with sarcoidosis. 61 54
19220835 2009
47
Bronchoalveolar lavage fluid cellular characteristics, functional parameters and cytokine and chemokine levels in interstitial lung diseases. 54 61
19281539 2009
48
Atypical sarcoidosis: case reports and review of the literature. 61 54
19530510 2009
49
Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease. 54 61
19077082 2009
50
Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? 54 61
19208587 2009

Variations for Sarcoidosis 1

ClinVar genetic disease variations for Sarcoidosis 1:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 HLA-DRB1 HLA-DRB1, HLA-DRB1*1101undetermined variant risk factor 14905

Expression for Sarcoidosis 1

Search GEO for disease gene expression data for Sarcoidosis 1.

Pathways for Sarcoidosis 1

Pathways related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 TNF SERPINA3 NOD2 IL2RA IL1B IL18
2
Show member pathways
13.85 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
3
Show member pathways
13.69 TNF IL2RA IL1B IL18 IL12RB1 IFNG
4
Show member pathways
13.57 TNF IL2RA IL1B IL18 IL12RB1 IFNG
5
Show member pathways
13.38 TNF NOD2 IL2RA IL1B IL18 IL12RB1
6
Show member pathways
13.38 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
7
Show member pathways
13.18 TNF IL2RA IL1B IL18 IL12RB1 CXCR3
8
Show member pathways
13.09 TNF IL1B IFNG CXCL9 CCL3 CCL2
9
Show member pathways
12.92 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
10
Show member pathways
12.89 TNF IL2RA IL1B IFNG HLA-DRB1 CXCL9
11
Show member pathways
12.87 TNF IL2RA IL1B IL18 IFNG HLA-DRB1
12 12.81 TNF IL1B IFNG HLA-DRB1 CCL2
13
Show member pathways
12.68 TNF IL2RA IL18 IL12RB1 IFNG HLA-DRB1
14 12.61 TNF IL2RA IL1B IFNG CCL2
15
Show member pathways
12.61 TNF IL1B IL18 IL12RB1 IFNG CXCL9
16
Show member pathways
12.46 TNF NOD2 IL2RA IL1B IL18 IL12RB1
17
Show member pathways
12.38 TNF SERPINA3 IL1B IFNG CCL2
18
Show member pathways
12.35 TNF IL1B IFNG CCL2
19
Show member pathways
12.31 TNF IL2RA IL1B IL18 IFNG
20 12.29 TNF NOD2 IL1B IL18 CCL2
21
Show member pathways
12.28 TNF IL1B IFNG HLA-DRB1
22 12.24 TNF NOD2 IL1B IL18 IFNG HLA-DRB1
23 12.13 TNF IL1B IFNG CCL2
24 12.06 TNF IL1B IL18 CCL2
25 12.06 TNF IL1B IFNG CCL2
26 12.03 TNF IL1B IL18 CCL2
27 12.01 TNF NOD2 IL1B CCL2
28
Show member pathways
12.01 TNF IL1B IL18 IL12RB1 IFNG
29 11.95 TNF IL2RA IL1B HLA-DRB1
30
Show member pathways
11.94 TNF IL2RA IL18 CXCR3 CXCL9 CCR6
31
Show member pathways
11.85 IL2RA IL1B IL18 IL12RB1 IFNG HLA-DRB1
32
Show member pathways
11.78 TNF IL2RA IFNG
33 11.76 TNF IL1B IFNG
34 11.73 TNF IL1B CCL3 CCL2
35
Show member pathways
11.69 TNF IL1B IFNG
36
Show member pathways
11.67 TNF IL2RA IFNG
37 11.67 TNF IL1B IL18 IFNG HLA-DRB1 CCL3
38 11.64 TNF IL1B IL18
39 11.56 TNF IL1B IFNG
40 11.55 TNF IL1B IL18 IFNG CCL2
41 11.53 TNF IL1B IFNG
42 11.52 TNF IL1B IL18 CCL3 CCL2
43 11.48 NOD2 IL1B IL18
44 11.48 TNF IL1B IL18 IFNG CCL2
45 11.47 TNF IL1B IL18 IFNG
46
Show member pathways
11.46 TNF IL2RA IFNG CCL3
47 11.43 IL1B IFNG CXCL9
48 11.39 TNF IL1B IL18 IFNG
49 11.32 TNF IL1B IFNG HLA-DRB1
50
Show member pathways
11.3 IL2RA IL12RB1 IFNG

GO Terms for Sarcoidosis 1

Cellular components related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
2 extracellular space GO:0005615 9.77 TNF SERPINA3 SCGB1A1 IL1B IL18 IFNG
3 cell surface GO:0009986 9.73 TNF NOD2 IL2RA HLA-DRB1 CXCR3 CCR6
4 external side of plasma membrane GO:0009897 9.28 TNF IL2RA IL12RB1 HLA-DRB1 CXCR3 CXCL9

Biological processes related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 63)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.29 SCGB1A1 IL1B IL18 IL12RB1 HLA-DRB1 CXCR3
2 positive regulation of gene expression GO:0010628 10.12 TNF IL1B IL18 IFNG CCL3
3 cell-cell signaling GO:0007267 10.04 IL1B IL18 CXCL9 CCL3 CCL18
4 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10 TNF NOD2 IL1B HLA-DRB1
5 positive regulation of protein phosphorylation GO:0001934 10 TNF IL1B IFNG HLA-DRB1
6 cellular response to lipopolysaccharide GO:0071222 10 TNF NOD2 IL1B CXCL9 CCL2
7 MAPK cascade GO:0000165 10 TNF IL2RA IL1B IL18 CCL3 CCL2
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 TNF NOD2 IL1B IL18
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 TNF NOD2 HLA-DRB1 CCL3 CCL2 CCL18
10 cellular response to interferon-gamma GO:0071346 9.93 IL12RB1 CCL3 CCL2 CCL18
11 cell chemotaxis GO:0060326 9.92 CXCR3 CCR6 CCL3 CCL2
12 calcium-mediated signaling GO:0019722 9.91 CXCR3 CCR6 CCL3
13 chemotaxis GO:0006935 9.91 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
14 cytokine-mediated signaling pathway GO:0019221 9.91 TNF IL2RA IL1B IL18 IL12RB1 CCL3
15 cellular response to interleukin-1 GO:0071347 9.9 CCL3 CCL2 CCL18
16 positive regulation of JNK cascade GO:0046330 9.9 TNF NOD2 IL1B
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 TNF IL18 IFNG
18 regulation of insulin secretion GO:0050796 9.89 TNF IL1B IFNG
19 positive regulation of T cell proliferation GO:0042102 9.88 IL2RA IL1B BTNL2
20 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF NOD2 IL1B IL18
21 positive regulation of inflammatory response GO:0050729 9.88 TNF IL1B IL18 IFNG CCL3
22 positive regulation of interleukin-6 production GO:0032755 9.87 TNF NOD2 IL1B
23 humoral immune response GO:0006959 9.87 TNF IFNG CCR6 CCL2
24 positive regulation of phagocytosis GO:0050766 9.86 TNF IL1B IFNG
25 monocyte chemotaxis GO:0002548 9.85 CCL3 CCL2 CCL18
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG
27 negative regulation of T cell proliferation GO:0042130 9.85 SCGB1A1 IL2RA HLA-DRB1
28 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF IL1B IFNG
29 neutrophil chemotaxis GO:0030593 9.85 IL1B CXCL9 CCL3 CCL2 CCL18
30 lymphocyte chemotaxis GO:0048247 9.84 CCL3 CCL2 CCL18
31 positive regulation of interferon-gamma production GO:0032729 9.84 TNF IL1B IL18 IL12RB1
32 positive regulation of interleukin-8 production GO:0032757 9.83 TNF NOD2 IL1B
33 positive regulation of activated T cell proliferation GO:0042104 9.83 IL2RA IL18 IL12RB1
34 protein kinase B signaling GO:0043491 9.81 TNF IL1B CCL3 CCL2
35 eosinophil chemotaxis GO:0048245 9.8 CCL3 CCL2 CCL18
36 inflammatory response to antigenic stimulus GO:0002437 9.8 IL2RA IL1B HLA-DRB1
37 astrocyte activation GO:0048143 9.79 TNF IL1B IFNG
38 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.78 TNF IL1B IFNG
39 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.77 NOD2 IFNG CCL2
40 positive regulation of chemokine biosynthetic process GO:0045080 9.75 TNF IL1B IFNG
41 detection of bacterium GO:0016045 9.73 NOD2 HLA-DRB1
42 T cell chemotaxis GO:0010818 9.73 CXCR3 CCL3
43 positive regulation of neuroinflammatory response GO:0150078 9.73 TNF IL1B IL18
44 chemokine-mediated signaling pathway GO:0070098 9.73 CXCR3 CXCL9 CCR6 CCL3 CCL2 CCL18
45 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.72 IL1B IL18
46 negative regulation of amyloid-beta clearance GO:1900222 9.72 TNF IFNG
47 T-helper 1 type immune response GO:0042088 9.72 IL18 HLA-DRB1
48 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 TNF IL1B IL18 CCL3 CCL2
49 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.71 TNF IFNG
50 interleukin-6 production GO:0032635 9.71 IL1B IL18

Molecular functions related to Sarcoidosis 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.33 CCL3 CCL2 CCL18
2 chemokine activity GO:0008009 9.26 CXCL9 CCL3 CCL2 CCL18
3 cytokine activity GO:0005125 9.23 TNF IL1B IL18 IFNG CXCL9 CCL3

Sources for Sarcoidosis 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....